Taking counterfeits out of the pharmaceutical supply chain in Nigeria: Leveraging multilayer mitigation approach

Journal of African Business

Volumn 10, Issue 2, 2009, Pages 218-234

  Enyinda, Chris I ^a   Tolliver, Denver ^b  

^a ALABAMA A AND M UNIVERSITY   (United States)

^b NORTH DAKOTA STATE UNIVERSITY   (United States)

Author keywords

Counterfeit pharmaceuticals; Patient welfare; Pharmaceutical supply chain; Pharmaceutical supply chain security and integrity; Public health confidence; Risk of counterfeit

Indexed keywords

HEALTH CARE; HEALTH RISK; MANAGEMENT PRACTICE; PHARMACEUTICAL INDUSTRY; PIRACY; PUBLIC HEALTH; RISK ASSESSMENT;

AFRICA; NIGERIA; SUB-SAHARAN AFRICA; WEST AFRICA;

EID: 70449091497     PISSN: 15228916     EISSN: 15229076     Source Type: Journal    
DOI: 10.1080/15228910903187957     Document Type: Article

References (36)

1. Akunyili, D. N. (2006). Strategies employed in combating counterfeiting in Nigeria. Retrieved November 16, 2007, from http://mednet3.who.int/cft/ PRESENTATIONS/Nigeria.ppt
2. Battling counterfeit drugs in Nigeria. (2004, May 28). The Wall Street Journal, A1.
3. Burns, W. (2006). WHO launches taskforce to fight counterfeit drugs. Bulletin of the World Health Organization. Retrieved May 20, 2008, from http://www.who.int/bulletin/volumes/84/9/06-010906/en/
4. Closs, D. J., & McGarrell, E. F. (2004, April). Enchancing security throughout the supply chain. IBM center for the business of government Retrieved May 30, 2008, from http://www.businessofgovernment.org/pdfs/Closs-Report.pdf
5. Cockburn, R., Newton, P. N., Agyarko, K. E., Akunyili, D., & White, J. N. (2005). The global threats of counterfeit drugs: Why industry and governments must communicate the dangers. Retrieved May 5, 2009, from http://www.plosmedicine.org/arDicle/info: doi/10.1371/ journal.pmed.0020100
6. Cohen-Kohler, J. (2007). Good governance in the pharmaceutical system: Why it is a matter of life and death. Retrieved May 5, 2009, from http://www.baselgovernance.org/fileadmin/docs/pdfs/Brownbag/ BBL-Cohen.pdf
7. Drucker, P. F. (1962, April). The economy's dark continent. Forture Magazine, 72 (103), 265-270.
8. Enyinda, C., & Szmerekovsky, J. (2007, May 3-6). Sense and respond model: A prescription for mitigating the U.S. pharmaceutical supply chain vulnerabilities and then risk of counterfeit drugs. In Proceedings of the International Academy of Business and Public Administration Disciplines, 4 (2), 1056-1070.
9. European Generic Medicines Association (2006, July 19). Business with certified partners only: Position paper on anti-counterfeit policy. Retrieved April 13, 2008, from www.egagenerics.com/doc/ ega-anticounterfeit_position.pdf
10. Gibson, L. M. (2004). Drug regulators study global treaty to tackle counterfeit drugs. British Medical Journal, 328 (7438), 486.
11. Hanif, M., Mobarak, M., Ronan, A., Rahman, D., Donovan, J. et al. (1995). Fatal renal failure caused by diethylene glycol in paracetamol exlixir: The Bangladesh epidemic. British Medical Journal, 311 88-91.
12. Hogerzeil, H. (1995). Promoting rational prescribing. British Journal of Clinical Pharmacology, 39, 1-6.
13. Hutin, Y., & Hauri, A. (2002, July 7-12). Poor injection practices in healthcare setting two decades into the HIV pandemic: Are we missing opportunities to prevent nosocomial HIV infections? In Proceedings of the XIV International AIDS Conference, Geneva, Switzerland.
14. International Federation of Pharmaceutical Manufacturers Association (IFPMA). (2004). Counterfeit drugs: A global health risk. Geneva Pharma Forum. Retrieved March 27, 2009, from www.quiminet.com/estm/files/ counterfeit_farma.doc
15. Jones, P. (2004). Building a healthier system: Improving efficiency and safety in the pharmaceutical supply chain. Retrieved from http://www.samedanltd.com/members/archives/PMPS/Spring2004/PeterJ.htm
16. King, B., & Zhang, X. (2007). Securing the pharmaceutical supply chain using RFID. Retrieved May 5, 2009, from http://ieeexplore.ieee.org/ Xplore/login.jsp?url=http%3A%2F%2Fieeexplore.ieee.org%2Fiel5% 2F4197230%2F4197231%2F04197244.pdf&authDecision=-203
17. Morris, J., & Stevens, P. (2006). Counterfeit medicines in less developed countries: Problems and solutions. Retrieved May 5, 2009, from http://www.fightingdiseases.org/pdf/IPN_Counterfeits.pdf
18. Nelson, M., Vizurraga, M., & Chang, D. (2006). Counterfeit pharmaceuticals: A worldwide problem. Journal of the International Trademark Association, 96 (5), 1068-1100.
19. Newton, P., Fernández, F. M., Green, M., Day, N., & White, N. J. (2006). Counterfeit anti-ineffective drugs. The Lancet, 6, 602-613.
20. Patton, S. (2006). Cracks in the Pharmaceutical Supply Chain. Retrieved April 13, 2008, from http://www.bio-itworld.com/newsitems/2006/january/ 11-18-06-news-supply-chain
21. Pearson, J. (2005). Securing the pharmaceutical supply chain with RFID and public-key infrastructure technologies. Retrieved April 13, 2008, from http://www.ti.com/rfid/docs/manuals/whtPapers/wp-RFID_and_PKI.pdf
22. Pecoul, B., Chirac, P., Trouiller, P., & Pine, J. (1999). Access to essential drugs in poor countries: A lost battle? Journal of the American Medical Association, 281, 361-367.
23. Quick, J. D. (2003). Ensuring access to essential medicines in the developing countries: A framework for action. American Society for Clinical Pharmacology and Therapeutics, 73 (4), 279-283.
24. Quick, J. D., Hogerveil, H. V., Rankin, J. R., Dukes, M. N. G., Laing, R. O., Garnet, A., & O'Connor, R. W. (1997). Managing drug supply: Towards sustainable supply and rational use of drugs (2nd edition). Westford, CT: Kumarian Press.
25. Rudolf, P. M., & Bernstein, I. B. (2004). Medical biology on counterfeit drugs. New England Journal of Medicine, 350, 1384.
26. Seiter, A. (2005). Pharmaceuticals: Counterfeits, substandard drugs and drug diversion. Retrieved April 13, 2008, from http://siteresources.worldbank.org/HEALTHNUTRITIONANDPOPULATION/ Resources/281627-1109774792596/HNP Brief_2_9Mar05.pdf
27. Shakoor, O., Taylor, R., & Behrens, R. (1997). Assessment of the incidence of substandard drugs in developing countries. Tropical Medicine & International Health, 2 (9), 839-845.
28. Spies, A. R., & Dusen, V. V. (2003). Counterfeit drugs: A menace keeps growing. Retrieved from http://www.uspharmacist.com/ index.asp?show=article&page=8_1014.htm
29. Stephan, C. (2005). RFID: A business perspective. Retrieved from www.ottawawirelesscluster.com/httpdocs/presentations/ RFIDOttawa13jan05.ppt
30. The Health Industry Group Purchasing Association (HIGPA). (2004). Integrity of the pharmaceutical supply chain: Product sourcing for patient safety. Retrieved from www.ashp.org/emplibrary/integrity.pdf
31. The Henry H. Kaiser Family Foundation. (2005). Follow the pill: Understanding the U.S. commercial pharmaceutical supply chain. Retrieved from http://www.kff.org/rxdrugs/upload/Follow-The-Pill-Understanding- the-U-S-Commercial-Pharmaceutical-Supply-Chain-Report.pdf
32. Wald, J. (2006). The pharmaceutical supply chain: A key to corporate profits and public protection. The Metropolitan Corporate Counsel.
33. World Health Organization. (2003). The quality of antimalarials: A study in seven African countries. Geneva: World Health Organization. Retrieved from http://whqlibdoc.who.int/hq/2003/WHO_EDM_PAR_2003.4.pdf
34. World Health Organization. (1998). Progress of WHO member states in developing national drug policies and revising essential drugs lists (WHO/DAP/98.7). Geneva: World Health Organization.
35. World Health Organization. General information on counterfeit medicines. Retrieved from http://www.who.int/medicines/services/counterfeit/ overview/en/
36. Wyld, C. D. (2008). Genuine medicine? Why safeguarding the pharmaceutical supply chain from counterfeit drugs with RFID is vital for protecting public health and the health of the pharmaceutical industry. Retrieved from http://www.allbusiness.com/government/ government-bodies-offices-us-federal-government/11683180-1.html